
November 18, 2022
UNC Lineberger faculty recognized as world’s most highly cited researchers
Twelve UNC Lineberger Comprehensive Cancer Center members were named to Clarivate’s 2022 Highly Cited Researchers list.
November 18, 2022
Twelve UNC Lineberger Comprehensive Cancer Center members were named to Clarivate’s 2022 Highly Cited Researchers list.
December 10, 2021
Fifteen UNC Lineberger Comprehensive Cancer Center members were named as 2021 Highly Cited Researchers by Clarivate for publishing some of the most influential scientific papers during the past decade.
October 6, 2021
Researchers from UNC Lineberger and colleagues report pairing a newly developed gel with immunotherapy that was delivered to post-surgical lab models with glioblastoma improved the immunotherapy’s effectiveness.
September 23, 2021
Hongwei Du, PhD, Gianpietro Dotti, MD, and colleagues developed a new therapeutic approach that has shown successful results in lab models.
April 23, 2021
Barbara Savoldo, MD, PhD, and Gianpietro Dotti, MD, have established a fund to develop a CAR-T therapy for glioblastoma in honor of Savoldo's sister, Sonia.
March 4, 2021
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
January 25, 2021
The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.
November 10, 2020
October 12, 2020
Zongchao Han, MD, PhD, Barbara Savoldo, MD, PhD, and colleagues report in Nature Cancer they used a combination of CAR-Ts and interleukin (IL)-15 to treat retinoblastoma in a mouse model.
December 3, 2018
At the 60th American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger's Natalie Grover, MD, presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.